Start with 2ml for most peptides
After this phase, we usually shift to a maintenance schedule of one injection every one to three months
Pharmacological risks : Even if the product is genuine, the adverse effect profile of retatrutide as observed in the published phase 2 clinical trial includes nausea, vomiting, diarrhoea, decreased appetite, and injection-site reactions
it is naturally occurring, nontoxic, and is active at a very low nanomolar concentration.11 Another piece of research described GHK-Cu as a safe, inexpensive, extensively studied compound.3 These conclusions primarily apply to topical GHK-Cu, but even with injectables, the lack of serious adverse events in animal subjects points to a general tolerability regardless of the route of administration